Drug Profile
Research programme: neuronal stem cell therapeutics - Samaritan/McGill University
Alternative Names: SP-sc4; SP-sc7Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Georgetown University; McGill University; Samaritan Pharmaceuticals
- Developer CHDI; McGill University; Samaritan Pharmaceuticals
- Class Small molecules; Stem cell factors
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Huntington's disease; Neurodegenerative disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Canada